These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7368984)

  • 1. Enteric coated quinidine compared to sustained release preparations during repeated administration.
    Bakke OM; Aanderud L; Aslaksen A
    Acta Med Scand; 1980; 207(3):183-7. PubMed ID: 7368984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption of quinidine from an enteric-coated preparation.
    Fremstad D; Nilsen OG; Amlie J; Storstein L; Olsson B; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):107-12. PubMed ID: 499306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of quinidine plasma concentration curves following oral administration of some short- and long-acting formulations.
    Frigo GM; Perucca E; Teggia-Droghi M; Gatti G; Mussini A; Salerno J
    Br J Clin Pharmacol; 1977 Aug; 4(4):449-54. PubMed ID: 901736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of three commercial sustained-release tablets of quinidine in maintenance therapy.
    Huynh-Ngoc T; Chabot M; Sirois G
    J Pharm Sci; 1978 Oct; 67(10):1456-9. PubMed ID: 702302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative bioavailability of three commercial quinidine dosage forms.
    Sirois G; Eshaque M; Chabot M
    Biopharm Drug Dispos; 1980; 1(4):167-77. PubMed ID: 7448345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute bioavailability of quinidine in two sustained release preparations.
    Amlie JP; Storstein L; Olsson B; Fremstad D; Jacobsen S
    Eur J Clin Pharmacol; 1979 Aug; 16(1):45-8. PubMed ID: 499299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability of a standard and a sustained-release quinidine tablet.
    Gibson DL; Smith GH; Koup JR; Stewart DK
    Clin Pharm; 1982; 1(4):366-8. PubMed ID: 7185532
    [No Abstract]   [Full Text] [Related]  

  • 10. Bioavailability of a commercial sustained-release quinidine tablet compared to oral quinidine solution.
    Sawyer WT; Pulliam CC; Mattocks A; Foster J; Hadzija BW; Rosenthal HM
    Biopharm Drug Dispos; 1982; 3(4):301-10. PubMed ID: 7159686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of food and tablet formulation on plasma prednisolone levels following administration of enteric-coated tablets.
    Lee DA; Taylor GM; Walker JG; James VH
    Br J Clin Pharmacol; 1979 May; 7(5):523-8. PubMed ID: 475947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
    Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
    Regårdh CG; Johnsson G; Lundborg P; Perrson BA
    Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quinidine dosage, with special reference to an oral loading dose schedule.
    Collste P; Nordlander R
    Br J Clin Pharmacol; 1979 Mar; 7(3):293-7. PubMed ID: 427006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioavailability study of three sustained release quinidine formulations.
    Mahon WA; Leeder JS; Brill-Edwards MM; Correia J; MacLeod SM
    Clin Pharmacokinet; 1987 Aug; 13(2):118-24. PubMed ID: 3621768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
    Ahmad M; Pervaiz F
    Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the absorption from some commercial enteric-release theophylline products.
    Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
    J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of plasma lithium levels and their interindividual variations with coated lithium carbonate tablets and a medium-slow-release lithium sulphate preparation (Lithionit Duretter).
    Persson G
    Acta Psychiatr Scand; 1977 Feb; 55(2):147-52. PubMed ID: 320831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation, bioavailability, and pharmacokinetics of sustained-release potassium chloride tablets.
    Senel S; Capan Y; Dalkara T; Inanç N; Hincal AA
    Pharm Res; 1991 Oct; 8(10):1313-7. PubMed ID: 1796051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.